Tecovirimat is an antiviral prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox in adults and children. (Smallpox is a disease caused by the variola virus, a member of the orthopoxvirus group of viruses. Since 1980, smallpox has been considered eradicated worldwide.) Although tecovirimat is only approved for smallpox treatment, it may also be used to treat other types of orthopoxvirus infections, including mpox. Tecovirimat is available for mpox treatment through a clinical trial or through an expanded access program. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include tecovirimatum, 4-trifluoromethyl-N-(3, 3a, 4, 4a, 5, 5a, 6, 6a-octahydro-1, 3-dioxo-4 and 6-ethenocycloprop(f)isoindol-2(1H)-yl)-benzamide. Its PubChem CID is 16124688.
Tecovirimat
| CAS No | 869572-92-9 |
|---|---|
| Molecular Formula | C19H15F3N2O3 |
| Molecular Weight | 376.3 g/mol |
| Synonyms | N-[(1S,2S,6R,7R,8R,10S)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
S. Food and Drug Administration (FDA) for the treatment of smallpox in adults and children. (Smallpox is a disease caused by the variola virus, a member of the orthopoxvirus group of viruses.
The listed CAS number is 869572-92-9.
The listed molecular formula is C19H15F3N2O3.
The listed molecular weight is 376.3 g/mol.
N-[(1S,2S,6R,7R,8R,10S)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide.
The source lists tecovirimatum, 4-trifluoromethyl-N-(3, 3a, 4, 4a, 5, 5a, 6, 6a-octahydro-1, 3-dioxo-4 and 6-ethenocycloprop(f)isoindol-2(1H)-yl)-benzamide.